Li Yanjun, Hu Huili, Wang Yuxing, Fan Yujia, Yang Yang, Guo Beibei, Xie Xueyong, Lian Jiabei, Jiang Baichun, Han Bo, Wang Yanlei, Shao Changshun, Gong Yaoqin
Key Laboratory of Experimental Teratology, Ministry of Education and Institute of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Oncogenesis. 2020 Feb 13;9(2):20. doi: 10.1038/s41389-020-0206-3.
Given that colorectal cancer stem cells (CCSCs) play key roles in the tumor dormancy, metastasis, and relapse, targeting CCSCs is a promising strategy in cancer therapy. Here, we aimed to identify the new regulators of CCSCs and found that Cullin 4B (CUL4B), which possesses oncogenic properties in multiple solid tumors, drives the development and metastasis of colon cancer by sustaining cancer stem-like features. Elevated expression of CUL4B was confirmed in colon tumors and was associated with poor overall survival. Inhibition of CUL4B in cancer cell lines and patient-derived tumor organoids led to reduced sphere formation, proliferation and metastasis capacity. Mechanistically, CUL4B coordinates with PRC2 complex to repress miR34a expression, thus upregulates oncogenes including MYCN and NOTCH1, which are targeted by miR34a. Furthermore, we found that elevated CUL4B expression is associated with miR34a downregulation and upregulation of miR34a target genes in colon cancer specimens. Collectively, our findings demonstrate that CUL4B functions to repress miR34a in maintaining cancer stemness in CRC and provides a potential therapeutic target.
鉴于结直肠癌干细胞(CCSCs)在肿瘤休眠、转移和复发中起关键作用,靶向CCSCs是癌症治疗中一种有前景的策略。在此,我们旨在鉴定CCSCs的新调节因子,并发现Cullin 4B(CUL4B)在多种实体瘤中具有致癌特性,通过维持癌症干细胞样特征驱动结肠癌的发展和转移。CUL4B在结肠肿瘤中的表达升高,并与总体生存率低相关。在癌细胞系和患者来源的肿瘤类器官中抑制CUL4B导致球体形成、增殖和转移能力降低。从机制上讲,CUL4B与PRC2复合物协同作用以抑制miR34a表达,从而上调包括MYCN和NOTCH1在内的致癌基因,这些基因是miR34a的靶标。此外,我们发现结肠癌标本中CUL4B表达升高与miR34a下调以及miR34a靶基因上调相关。总的来说,我们的研究结果表明,CUL4B在维持CRC的癌症干性方面发挥抑制miR34a的作用,并提供了一个潜在的治疗靶点。